Drug targets in the cytokine universe for autoimmune disease
Authors:
- Lei FangLFLei Fang
- Taylor B. GuoTGTaylor B. Guo
- Hongkang MeiHMHongkang Mei
- Jingwu Z. ZhangJZJingwu Z. Zhang
- 1 March 2013
- journal article
- review article
- Published by Elsevier in Trends in Immunology
- Vol. 34 (3) , 120-128
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Type 1 regulatory T cells (Tr1) in autoimmunitySeminars in Immunology, 2011
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitisNature Medicine, 2010
- Plasticity of CD4+ FoxP3+ T cellsCurrent Opinion in Immunology, 2009
- Role of Th1 and Th17 cells in organ-specific autoimmunityJournal of Autoimmunity, 2008
- The Foxp3+ regulatory T cell: a jack of all trades, master of regulationNature Immunology, 2008
- Phenotypic and functional features of human Th17 cellsJournal of Experimental Medicine, 2007
- Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammationNature Medicine, 2007
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003